WT161

10/06/2017 - "In this study, we further evaluated the biologic sequelae of WT161 in breast cancer cell lines. "
08/17/2021 - "Correction: HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer."
10/06/2017 - "Finally, WT161 synergistically enhances bortezomib-induced cytotoxicity, even in bortezomib-resistant breast cancer cells. "
10/06/2017 - "HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer."
12/01/2019 - "WT161 is a recently discovered histone deacetylase 6 (HDAC6) inhibitor which shows anti-tumor effects on multiple myelomas and breast cancer. "

01/01/2021 - "The aim of the present study is to explore the roles of WT161 in osteosarcoma and its underlying mechanisms. "
01/01/2021 - "Rep.41, DOI: 10.1042/BSR20203905) identified that WT161 suppresses the cell growth of osteosarcoma cells. "
01/01/2021 - "WT161 suppressed the cell growth and induced apoptosis of osteosarcoma cells in a dose- and time-dependent manner. "
01/01/2021 - "The osteosarcoma xenograft models were established to evaluate the anti-proliferative effect of WT161 in vivo. "
01/01/2021 - "The anti-proliferative effect of WT161 on osteosarcoma cells was examined using MTT assay and colony formation assay. "

12/01/2019 - "The aim of this study is to explore the role of WT161 in retinoblastoma and its underlying mechanisms. "
12/01/2019 - "These results indicate that WT161, as a selective HDAC6 inhibitor, is a promising agent against retinoblastoma."
12/01/2019 - "WT161 suppressed the cell growth and induced apoptosis of retinoblastoma cells in a dose- and time-dependent manner. "
12/01/2019 - "However, the role of WT161 in retinoblastoma remains unclear. "
12/01/2019 - "In addition, WT161 shows synergistically inhibitory effects on retinoblastoma cell combined with cisplatin. "

01/01/2022 - "In this study, we have shown that WT161, an inhibitor of HDAC6, exerts a protective role in a colitis model, blocks NLRP3 inflammasome activation, disrupts ASC speck formation, and decreases the expression of NLRP3. "
01/01/2022 - "Identification of WT161 as a Potent Agent for the Treatment of Colitis by Targeting the Nucleotide-Binding Domain-Like Receptor Family Pyrin Domain Containing 3 Inflammasome."

01/01/2021 - "WT161, as a selective HDAC6 inhibitor, has been shown to play anti-tumor effects on several kinds of cancers. "
01/01/2021 - "Targeting the 'garbage-bin' to fight cancer: HDAC6 inhibitor WT161 has an anti-tumor effect on osteosarcoma and synergistically interacts with 5-FU."
01/01/2021 - "HDAC6 inhibitor WT161 performs anti-tumor effect on osteosarcoma and synergistically interacts with 5-FU."
12/01/2019 - "WT161 is a recently discovered histone deacetylase 6 (HDAC6) inhibitor which shows anti-tumor effects on multiple myelomas and breast cancer. "